Physicians' Academy for Cardiovascular Education

Positive results with SGLT2 inhibitor in patients with diabetic kidney disease across all levels of eGFR

3' education - Apr. 17, 2019

Reduction in renal outcomes with selective endothelin receptor antagonist in patients with diabetic kidney disease

3' education - Apr. 17, 2019 - Melbourne, Australia

Endothelin receptor antagonist gives renoprotection in selected patients with T2DM and CKD

3' education - Apr. 15, 2019 - Melbourne, Australia

Hopeful results with SGLT2 inhibitor in patients with T2DM and chronic kidney disease

3' education - Apr. 15, 2019 - Melbourne, Australia

Detection of AF with wearable technology to prevent stroke

3' education - Apr. 8, 2019

Improved QoL with transcatheter mitral valve repair in HF patients with secondary mitral regurgitation

3' education - Apr. 8, 2019

Centrifugal-flow pump superior to axial-flow pump for clinical outcomes in advanced HF

3' education - Apr. 8, 2019

No difference in survival with immediate vs. delayed coronary angiography after cardiac arrest in NSTEMI patients

3' education - Apr. 8, 2019 - Jorrit Lemkes

Clinical benefit with SGLT2 inhibitor in diabetes patients with HF independent of ejection fraction

3' education - Apr. 8, 2019 - Dr. Eri Kato, Kyoto, Japan

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh

Device safely keeps HF patients out of the hospital

3' education - Mar. 17, 2019

Long-term data confirm safety and efficacy of oral antibiotics in left-sided endocarditis

3' education - Mar. 27, 2019

TAVR vs surgery in aortic stenosis: reason for a paradigm flip?

3' education - Mar. 19, 2019 - New Orleans, LA, USA - Janet Wyman

Highly purified omega-3 fatty acid not only lowers first ischemic events, but also recurrent events

3' education - Mar. 19, 2019 - Deepak L. Bhatt, MD

Benefits of early initiation of ARNI in acute HF confirmed in open-label extension study

3' education - Mar. 19, 2019 - Adam DeVore, MD

Cholesterol synthesis inhibitor has potential to be add-on therapy to statin in patients with high CV risk

3' education - Mar. 19, 2019 - Anne Carol Goldberg, MD

Substantial reduction in clinical outcomes with TAVR in aortic stenosis patients at low surgical risk

3' education - Mar. 19, 2019 - New Orleans, LA, USA - Martin B. Leon, MD

Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin

3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD

Proof-of-concept study shows 84% true AF in those with irregular pulse detected with smartwatch

3' education - Mar. 16, 2019 - New Orleans, LA, USA - Michael Valentine, MD

Lifestyle improvement forms foundation of comprehensive guideline for primary prevention

3' education - Mar. 16, 2019 - New Orleans, LA, USA - Dr. Amit Khera

Reversal agent for antiplatelet effect of P2Y12 inhibitor receives FDA Breakthrough Therapy designation

News - Apr. 18, 2019

FDA Breakthrough Therapy designation has been granted to PB2452, a reversal agent for ticagrelor-induced platelet inhibition.

Rapid and sustained reversal of P2Y12 inhibitor-induced platelet inhibition with reversal agent

Literature - Apr. 18, 2019 - Bhatt DL, et al. - N Eng J Med 2019

Infusion of the reversal agent PB2452 resulted in immediate and sustained reversal of platelet inhibition by the P2Y12 inhibitor ticagrelor in healthy volunteers in a phase 1 trial.

Low LDL-c and TG levels associated with risk of hemorrhagic stroke in women

Literature - Apr. 18, 2019 - Rist PM et al., - Neurology 2019

In a large, prospective cohort of women, those with LDL-c <70 mg/dL and potentially those with LDL-c ≥160 mg/dL and those with low TG, showed a higher risk of hemorrhagic stroke.

Renal denervation associated with SBP reduction in meta-analysis of sham-controlled trials

Literature - Apr. 17, 2019 - Sardar P et al., - J Am Coll Cardiol. 2019

Analysis of data of six randomized sham-controlled trials of renal sympathetic denervation, shows that RSD gave greater reduction in 24-h ambulatory, daytime ambulatory and office SBP and DBP.

Positive results with SGLT2 inhibitor in patients with diabetic kidney disease across all levels of eGFR

3' education - Apr. 17, 2019
SGLT2 inhibition in T2DM patients with kidney disease resulted in reduction of renal and CV outcomes, irrespective of baseline kidney dysfunction. Prof Carol Pollock discusses the results of the CREDENCE trial.

ISN-WCN 2019 SGLT2 inhibition in T2DM patients with kidney disease resulted in reduction of renal and CV outcomes, irrespective of baseline kidney dysfunction. Prof Carol Pollock discusses the results of the CREDENCE trial.

Reduction in renal outcomes with selective endothelin receptor antagonist in patients with diabetic kidney disease

3' education - Apr. 17, 2019 - Melbourne, Australia
Prof. Hiddo Lambers Heerspink dissusses the unique design of the SONAR trial and the findings with atrasentan therapy in patients with diabetic kidney disease.

ISN-WCN 2019 Prof. Hiddo Lambers Heerspink dissusses the unique design of the SONAR trial and the findings with atrasentan therapy in patients with diabetic kidney disease.

Oral GLP-1RA superior in reducing HbA1c compared to DPP-4 inhibitor in T2DM

Literature - Apr. 16, 2019 - Rosenstock J, et al. - JAMA 2019

In the PIONEER 3 trial, dosage of 7 and 14 mg oral semaglutide resulted in greater reductions of HbA1c compared to sitagliptin in T2DM patients.

Endothelin receptor antagonist gives renoprotection in selected patients with T2DM and CKD

3' education - Apr. 15, 2019 - Melbourne, Australia
The SONAR trial was designed to safely test the effect of atrasentan in a selected group of high-risk T2DM patients with kidney disease. This proved to be a good approach, as results were very positive.

ISN-WCN 2019 The SONAR trial was designed to safely test the effect of atrasentan in a selected group of high-risk T2DM patients with kidney disease. This proved to be a good approach, as results were very positive.

Hopeful results with SGLT2 inhibitor in patients with T2DM and chronic kidney disease

3' education - Apr. 15, 2019 - Melbourne, Australia
Prof. Perkovic summarizes the results of the CREDENCE trial that tested the SGLT2 inhibitor canagliflozin. It is a safe drug that prevents kidney failure and CV complications in people with diabetes and kidney disease.

ICN-WCN 2019 Prof. Perkovic summarizes the results of the CREDENCE trial that tested the SGLT2 inhibitor canagliflozin. It is a safe drug that prevents kidney failure and CV complications in people with diabetes and kidney disease.

Endothelin A receptor antagonist reduces renal events in selected high-risk T2DM patients

Literature - Apr. 15, 2019 - Lambers Heerspink HJ, et al., - The Lancet 2019

ISN-WCN 2019 In selected patients with T2DM and CKD, treatment with atrasentan significantly reduced the risk of the primary composite outcome of doubling of serum creatinine or end-stage kidney disease.

SGLT2 inhibition lowers risk of kidney failure in patients with T2DM and kidney disease

Literature - Apr. 15, 2019 - Perkovic V et al., - New Engl J Med. 2019
In the CREDENCE study, patients with T2DM and CKD who were treated with the SGLT2 inhibitor canagliflozin had a lower risk of renal and CV outcomes than those randomized to placebo.

ISN-WCN 2019 In the CREDENCE study, patients with T2DM and CKD who were treated with canagliflozin had a lower risk of renal and CV outcomes than those randomized to placebo.

Majority of statin-eligible US adults not taking a statin were never offered the therapy

Literature - Apr. 11, 2019 - Bradley CK et al. - J Am Heart Assoc. 2019

The PALM registry reveals that 27% of adults who were eligible for statin therapy, did not use it. In almost 60%, this was because they were never offered a statin. Others discontinued, or declined use